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ABSTRACT: Metabolic disease is a significant problem that causes a range of species-19 
specific co-morbidities. Recently, a better understanding of glucose-dependent insulinotropic 20 
polypeptide (GIP) biology has led to the suggestion that inhibiting its action may attenuate 21 
obesity in several species. In horses, antagonism of GIP may also reduce hyperinsulinemia, 22 
which leads to insulin-associated laminitis, a painful co-morbidity unique to this species. 23 
However, little is known about GIP in horses. The aims of this study were to examine the 24 
tissue distribution of equine GIP receptors (eGIPR), determine whether eGIPR can be 25 
blocked using a GIP antagonist not tested previously in horses, and to establish whether there 26 
is any association between GIP concentrations and body mass in this species. Archived 27 
tissues from healthy horses were used to establish that eGIPR gene expression was strong in 28 
pancreas, heart, liver, kidney and duodenum, and absent in gluteal muscle. Pancreatic islets 29 
were isolated from fresh horse pancreas using collagenase digestion and layering through a 30 
density gradient. Islet viability was confirmed microscopically and by demonstrating that 31 
insulin production was stimulated by glucose in a concentration-dependent manner. Insulin 32 
release was also shown to be concentration-dependent with GIP up to 0.1µM, and the 33 
response to GIP was decreased (P = 0.037) by the antagonist (Pro3)GIP. As for the 34 
relationship between body mass and GIP in vivo, post-prandial GIP concentrations in 35 
archived plasma samples were positively correlated with body condition and cresty neck 36 
scores (P < 0.05). Thus, the eGIPR is a potential therapeutic target for insulin dysregulation 37 
and obesity in horses. 38 
Key words: equine metabolic syndrome, glucose-dependent insulinotropic polypeptide 39 
receptor, horse, incretin, insulin, laminitis40 
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INTRODUCTION 41 
Obesity and metabolic disease precipitate attributive health problems that differ between 42 
species (Geor and Frank, 2009; Grundy, 2012). Horses develop a variant of metabolic 43 
syndrome (EMS), but rarely progress beyond a pre-diabetic state (Frank and Tadros, 2014). 44 
Principally, they exhibit insulin dysregulation, which can manifest as pulsatile (usually post-45 
prandial) or persistent hyperinsulinemia (Frank et al., 2010; de Laat et al., 2016). The primary 46 
sequela to insulin dysregulation is laminitis, a painful hoof disease of ungulates (McGowan, 47 
2008). 48 
 49 
Gastrointestinal hormones play an important role in the development of insulin dysregulation 50 
(Nguyen et al., 2012; Campbell and Drucker, 2013). In particular, incretin hormones enhance 51 
insulin release after nutrient intake and are therapeutic targets for metabolic disease in other 52 
species (Tiwari, 2015; Wu et al., 2015). However, the incretin effect differs between species, 53 
being more pronounced in humans (Nauck et al., 1986) than horses (de Laat et al., 2016). 54 
Thus, a species-specific approach to investigating incretin-based therapies is required 55 
(Renner et al., 2016). 56 
 57 
Glucose-dependent insulinotropic polypeptide (GIP) is an incretin that stabilises blood 58 
glucose concentration, promotes the proliferation and survival of pancreatic β-cells and 59 
modulates obesity (Drucker, 2013; Ceperuelo-Mallafre et al., 2014). Currently our 60 
understanding of GIP physiology in horses is limited. For example, there are no published 61 
data on the distribution of equine GIPR (eGIPR) and our first aim was to address this. 62 
Secondly, it is not known whether GIP action can be inhibited in the horse. Our second aim 63 
tested the hypothesis that GIP action can be attenuated using the antagonist (Pro3)GIP, which 64 
required us to isolate equine pancreatic islets and demonstrate their functionality in vitro. Our 65 
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final aim was determine if any relationship exists in vivo between circulating GIP 66 
concentrations and body condition in the horse.  67 
 68 
MATERIALS AND METHODS 69 
eGIPR Gene Expression 70 
For gene expression studies, samples of pancreas were obtained from five, healthy, mixed-71 
breed horses (Equus caballus, < 15 years old) immediately following euthanasia at a 72 
commercial abattoir in South East Queensland, Australia and snap-frozen. Archived samples 73 
of the left ventricle of the heart, kidney, digital lamellae, tongue, skeletal muscle and 74 
duodenum obtained from four healthy horses during a previous study (SVS/013/08/RIRDC) 75 
were also used. Tissue use approval was granted by the Animal Ethics Committee of 76 
Queensland University of Technology (1400000039). Tissue samples (50-100 mg) were 77 
homogenised (Omni International, Kennesaw, GA, USA) prior to total RNA extraction using 78 
Trizol reagent (1 mL/100 mg tissue) according to the manufacturer’s instructions (Invitrogen, 79 
Scoresby, Vic, Australia). The RNA pellet for each sample was treated with RNAse-free 80 
DNAse I (Invitrogen, Scoresby, Vic, Australia) to eliminate genomic DNA contamination. 81 
The integrity and concentration of the RNA was determined for each sample using a 2100 82 
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) prior to cDNA synthesis. 83 
 84 
The cDNA was synthesised from Dnase-treated RNA in a total volume of 20 µL, according 85 
to the Tetro cDNA Synthesis Kit protocol (Bioline, Alexandria, NSW, Australia). Each 86 
reaction contained 1 µg of cDNA, 1 µL Oligo (dT)18, 4 µL of 5x RT Buffer, 1 µL RiboSafe 87 
Rnase Inhibitor, 1 µL Tetro Reverse Transcriptase (200 µg/µL) made up to 20 µL with 88 
DEPC-treated water. Harvested cDNA was stored at -80°C until polymerase chain reaction 89 
(PCR) analysis. The eGIPR primers (forward: 5’-TGGAAAGTTACTGCTAGGGAGC-3’, 90 
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reverse: 5’-CCCACTTCTCCCTCTCCATCT-3’) were designed using Primer-BLAST (Ye et 91 
al., 2012) and primer concentration and PCR conditions were optimised prior to use. The 92 
reference gene selected was GAPDH (GenBank Accession Number: AF157626; forward 93 
primer: 5’-GATTGTCAGCAATGCCTCCT-3’, reverse primer: 5’-94 
AAGCAGGGATGATGTTCTGG-3’). No template, negative controls containing water 95 
instead of cDNA were included in each experiment.  96 
 97 
After optimisation, PCR was performed using the OneTaq Hot Start Quick-Load 2X Master 98 
Mix protocol (New England BioLabs Inc., Ipswich, MA, USA). Each 25 µL reaction 99 
contained 50 ng cDNA, 12.5 µL OneTaq Master Mix Buffer, 10 pm/µL of each primer 100 
(forward and reverse), and 10.5 µL deionised water (dH2O). The PCR cycle protocol 101 
involved 94°C for 30 sec, 40 cycles of 94°C for 30 sec, 52°C for 15 sec, and 68°C for 1 min, 102 
with final extension at 68°C for 5 min. Following cycling, PCR products were visualised with 103 
2% agarose gel electrophoresis. The PCR products were purified using an ISOLATE II PCR 104 
and Gel Kit (Bioline, Alexandria, NSW, Australia) and sequenced using a standard protocol 105 
on an ABI 3500 sequencing platform (Applied Biosystems, Carlsbad, CA, USA). Sequencing 106 
confirmed amplification of the desired target and reference genes.  107 
 108 
Pancreatic Islet Isolation 109 
Following collection at the abattoir, fresh pancreatic tissues were immediately irrigated with 110 
0.9% NaCl (Baxter, Old Toongabbie, NSW, Australia), blotted and placed in 500 mL of 111 
oxygenated (Carbogen) Krebs-Ringer buffer (KRB: NaCl 129 mM, NaHCO3 5 mM, KCl 4.8 112 
mM, MgSO4 1.2 mM, CaCl2 2.5 mM, HEPES 10 mM, BSA 0.1% at pH 7.4) for 113 
transportation (10 min) to the laboratory. The technique developed for equine pancreatic islet 114 
isolation was based on a validated protocol used in rats (Carter et al., 2009a), with some 115 
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modifications. Two lobes of pancreatic tissue from the same horse (300-550 g) were 116 
transferred from the transport buffer and placed together into sterile (0.22 µm syringe filters; 117 
Millex-GV, Merck, Bayswater, Vic, Australia) G-solution [1x Hanks balanced salt solution 118 
(HBSS; Gibco, Life Technologies, Mulgrave, Vic, Australia), 0.35 g NaHCO3/L and 1% 119 
BSA] for 5 min. The tissue was then distended with 5-6 mL of C solution [1.4 mg/mL 120 
collagenase-P (Roche, Mannheim, Germany) in G-solution] using a 25 gauge needle and left 121 
for 5 min at room temperature (RT). Following this initial digestion, the tissue was dissected 122 
(0.5 cm3) and 4 pieces were placed in one 15 mL falcon tube containing 5 mL of C solution 123 
(six tubes were prepared). The tubes were incubated for 15-20 min at 37°C in a shaking water 124 
bath (Ratek, Boronia, Vic, Australia). The tissue was then further gently broken up using a 125 
transfer pipette and/or hand agitation for 5 sec. The reaction was stopped by adding 10 mL 126 
ice-cold G solution prior to washing 3 times with 10 mL G solution for 10 min at RT and 290 127 
x g with gentle sieving (Rowe Scientific, Sumner Park, Qld, Australia). The tissue was then 128 
layered through a density gradient using 10 mL Histopaque 1.1 g/mL (25 mL of 1.077 and 35 129 
mL of 1.119 g/mL; Sigma Aldrich, Castle Hill, NSW, Australia) and centrifuged (RT; 20 130 
min; 290 x g). The supernatant (containing the islets) from 3 tubes (of the same pancreas) 131 
was combined and diluted in 25 mL of G solution. Islets were retrieved by centrifugation 132 
(RT; 4 min; 493 x g) and resuspension of the pellet in 10 mL of G solution, followed by 133 
washing 3 times (RT; 3 min; 290 x g). The final pellet was resuspended in 1 mL of G solution 134 
and examined microscopically (Premiere, Cumming, GA, USA) for islet integrity, purity and 135 
approximate yield. Isolations with < 80% live islets were discarded. 136 
 137 
In order to assess the viability of the isolated islets, equal aliquots of pelleted islets were re-138 
suspended (0.5 mL) and added to a 24-well-plate containing 0.5 mL of KRB and allowed to 139 
pre-incubate for 10 min prior to the addition of glucose to achieve a final glucose 140 
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concentration of 0, 1, 2, 4, 8, or 16 mM. An identical viability experiment was performed in 141 
parallel using tissue explants in order to enable a direct comparison between pancreatic tissue 142 
(the currently available in vitro technique) and islets in terms of their responsiveness to 143 
glucose.  144 
 145 
For the tissue incubations, pancreatic explants (~50 mg) were placed in 1 mL KRB with a 146 
glucose concentration of 0, 1, 2, 4, 8 or 16 mM. Both isolated islets (in triplicate; mean CV 147 
12%) and tissue explants (in quadruplicate; mean CV 14.6%) were incubated for 60 min at 148 
RT. After incubation, the tissue was removed, or the incubation medium centrifuged (RT; 149 
16,400 x g, 30 s), to pellet the islets and the supernatant was retained for both islet and tissue 150 
incubations. The protein concentration of each sample/pellet was determined in triplicate 151 
(mean intra-assay CV = 3.8%; mean inter-assay CV = 5.6%) using the bicinchoninic acid 152 
assay (Pierce, Rockford, IL, USA). The supernatant was stored at -80° C until analysed for 153 
insulin concentration using a validated equine ELISA kit (Mercodia, Uppsala, Sweden). The 154 
mean intra- and inter-assay CVs for this assay were 8.3% and 9.1%, respectively. The insulin 155 
production for each reaction was normalised to protein concentration and corrected for basal 156 
insulin secretion. 157 
 158 
Stimulation of Pancreatic Islets with GIP Analogues 159 
A series of concentration-response experiments was performed using freshly isolated equine 160 
pancreatic islets to determine the insulin response to human GIP (G2269; Sigma Aldrich, 161 
Castle Hill, NSW, Australia). This product was used because an equine-specific product was 162 
not available. Aliquots (0.5 mL) of pancreatic islets were added to wells containing 0.5 mL 163 
G-solution (final glucose concentration 2.75 mM) and allowed to pre-incubate for 10 min 164 
prior to the addition of increasing concentrations of GIP (1x10-12, 1x10-11, 1x10-10, 1x10-9 and 165 
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1x10-7 M). Samples were incubated in triplicate (mean CV was 6.4%) for 60 min at RT prior 166 
to centrifugation (RT; 7 min; 16,400 x g) to separate the supernatant from the cells. The 167 
supernatant was immediately frozen and stored at -80°C until analysis. The islets were 168 
solubilised prior to protein extraction and quantification as outlined above. 169 
 170 
Subsequently, the ability of the GIPR antagonist (Pro3)GIP (Biocore, Alexandria, NSW, 171 
Australia) to prevent GIP-stimulated insulin production from islets was assessed under the 172 
same incubation conditions, with the addition of (Pro3)GIP to the incubation media prior to 173 
adding the islets. Antagonism was tested at 1x10-10 M of GIP (n = 4 horses) using a 174 
(Pro3)GIP concentration of 1x10-9 M (Gault et al., 2003).  175 
 176 
Given that GIP has been shown to promote β-cell proliferation, the islets were analysed for 177 
evidence of any effect of the antagonist (Pro3)GIP on the amount of cellular proliferative and 178 
apoptotic activity occurring during the incubation described above with the agonist, GIP. 179 
Caspase 3 and proliferating cell nuclear antigen (PCNA) were used as markers of apoptosis 180 
and proliferation, respectively. Colorimetric equine-specific ELISA kits (MyBioSorce, San 181 
Diego, CA, USA) were used to determine caspase 3 and PCNA concentrations. The mean 182 
intra-assay CVs for the caspase 3 and PCNA assays were 3.2% and 7.7%, respectively. 183 
Absorbance was measured at 450 nm using a plate reader (Glomax Explorer, Promega, WI, 184 
USA).  185 
 186 
Correlation of Circulating GIP and Body Condition 187 
The study in vivo used archived plasma samples collected during a previous investigation of 188 
incretin action in nine, mixed-breed ponies (de Laat et al., 2016). The collection and use of 189 
these samples was approved by the Animal Ethics Committee of the University of 190 
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Queensland (SVS/QUT/109/13/QUT). Plasma samples were collected from nine (4 female, 5 191 
male; 14.1 ± 2.5 years), mixed-breed ponies 30, 60, 90 and 180 min after a voluntarily-192 
consumed dose of dextrose (0.75 g/kg bwt). The blood samples were collected into pre-193 
chilled EDTA tubes and immediately placed on ice for10 min, prior to centrifugation for 10 194 
min at 1,500 x g, separation of the plasma, and immediate freezing at -80˚C of a 1 mL 195 
aliquot. This blood collection protocol has been previously validated for incretin 196 
measurement in horses (de Laat et al., 2016). Plasma GIP concentration was measured in 197 
duplicate (mean intra-assay CV was 6.2%) with an ELISA (Merck Millipore, Germany) 198 
validated for use in horses (de Laat et al., 2016).  199 
 200 
Each pony was examined by a veterinary surgeon experienced in assigning body condition 201 
(BCS) and cresty neck (CrNS) scores to ponies as markers of generalised and regionalised 202 
adiposity, respectively, according to published, commonly-utilised scales (Henneke et al., 203 
1983; Carter et al., 2009b). The pony cohort was assessed for metabolic disease using both 204 
physical parameters and an oral glucose test, and consisted of both normal (n = 4) ponies, and 205 
ponies with EMS (n = 5). 206 
 207 
Statistical Analyses 208 
The data were distributed normally (Shapiro-Wilk test). The average amount of insulin 209 
produced by the tissue explants was compared to islet insulin production using an unpaired t-210 
test. The GIP-stimulated insulin production for each horse was compared with and without 211 
the addition of (Pro3)GIP using a paired t-test. Caspase 3 and PCNA concentrations in the 212 
islet extracts were compared in the presence and absence of (Pro3)GIP using a paired t-test. 213 
The maximum (Cmax), post-dextrose GIP concentration for each pony was correlated with 214 
BCS and CrNS using Pearson’s correlation test. Significance was set at P < 0.05 and the data 215 
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are reported as mean ± s.e.m. Data analyses were performed with SigmaPlot v.12.5 (Systat 216 
software, San Jose, CA, USA). 217 
 218 
RESULTS 219 
eGIPR Gene Expression 220 
As expected, gene expression of the eGIPR was consistent for all horses and was confirmed 221 
in the pancreas, with >98% sequence identity to E. caballus mRNA sequence available from 222 
GenBank (XM_001917029). The pancreas was used as a positive control for the remaining 223 
PCR runs. Electrophoresis of the PCR products from the other tissues detected eGIPR gene 224 
expression in the heart, liver, kidney and duodenum. Faint banding was detected in the digital 225 
lamellae and the tongue. There was no evidence of eGIPR gene expression in the gluteal 226 
skeletal muscle (Fig. 1). The GAPDH gene transcript was amplified in all tissues (Fig. 1). 227 
 228 
Validation of Islet Isolation Method 229 
Functional equine pancreatic islets were isolated successfully for the first time (to our 230 
knowledge). Insulin secretion by the islets was increased by glucose in a concentration-231 
dependent manner up to a glucose concentration of 4 mM, but with a possible glucotoxic 232 
effect and less (P = 0.02) insulin production at 16 mM (Fig. 2A). Overall, the isolated islets 233 
secreted 73% more insulin (± 0.07%; P = 0.047) than the tissue explants (per mg of protein) 234 
over the range of glucose concentrations tested. Insulin production by the explants peaked at 235 
8 mM glucose and was lower (P < 0.05) than the islets (per mg of protein) at 4, 8 and 16mM 236 
glucose (Fig 2A). Based on these data, isolated islets were used for all future experiments and 237 
a basal glucose concentration of 2.75 mM was selected for the incubation medium for the 238 
GIP analogue experiments. This glucose concentration was expected to support basic cell 239 
function, without stimulating insulin secretion markedly.  240 
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 241 
The Response to GIP Analogues 242 
Basal insulin secretion in the absence of GIP (130 ± 10 µIU/mg protein) was consistent with 243 
that expected in the presence of 2.75 mM glucose, based on the glucose stimulation 244 
experiment (Fig. 2B). Insulin release was stimulated by GIP in a concentration-dependent 245 
manner, with insulin concentrations reaching 299 µIU/mg protein at the maximum 246 
concentration (0.1µM) of GIP tested (Fig. 2B). The insulin secretory effect of GIP was 247 
inhibited by 30% (P = 0.037) in the presence of (Pro3)GIP (Fig. 2C). When islets were 248 
incubated with GIP in the absence or presence of the antagonist (Pro3)GIP, there was no 249 
effect on caspase 3 or PCNA concentration (Table 1).  250 
 251 
Correlation of Circulating GIP and Body Condition 252 
Due to the range of phenotypes and variation in the metabolic status of the ponies included in 253 
the study, the BCS ranged from 4/9 to 9/9 and the CrNS ranged from 0/5 to 4/5. The post-254 
prandial plasma GIP Cmax also varied considerably between individuals, with concentrations 255 
ranging from 18.3 pM to 58.9 pM. Circulating GIP Cmax was positively correlated (P < 256 
0.05) with both BCS and CrNS in the cohort of ponies examined (Fig. 3).  257 
 258 
DISCUSSION 259 
This study has confirmed the presence and functionality of the eGIPR. The eGIPR transcript 260 
was present in the pancreas, as expected based on findings in other species (Fujita et al., 261 
2010) and prior studies indicating a functional GIP axis that responds to oral carbohydrates in 262 
horses and ponies (Dühlmeier et al., 2001; de Laat et al., 2016). Although the eGIPR protein 263 
was not studied, the results suggest that the pancreatic eGIPR transcript detected in normal 264 
horses responded to native GIP in vitro, by stimulating insulin release in a concentration-265 
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dependent manner, as has been demonstrated with pancreatic islets isolated from other 266 
species (Fujita et al., 2010). In establishing this outcome the current study has also presented 267 
a valid methodology for the isolation of functional equine pancreatic islets, thus providing a 268 
valuable technique for further study of equine incretin biology. 269 
 270 
The principal hypothesis of this study was supported. It was demonstrated that not only was 271 
insulin secretion from equine islets dose-dependent with GIP, but that GIP-stimulated insulin 272 
secretion could be attenuated with the use of the GIPR antagonist (Pro3)GIP. This finding 273 
suggests that inhibition of GIP action may be achievable in vivo in horses through the 274 
administration of GIPR antagonists, and the pharmacokinetics and pharmacodynamics of 275 
these compounds is worth investigating. The GIPR antagonist (Pro3)GIP is, to date, the most 276 
thoroughly investigated compound for inhibition of GIP action, although small molecule 277 
receptor antagonists and neutralizing antibodies against GIP have also been studied (Finan et 278 
al., 2016). Recent studies have indicated that (Pro3)GIP appears to have species-specific and 279 
dose-dependent actions, with a switch from being an antagonist to a weak partial agonist at 280 
high doses in humans and mice, but not rats (Sparre-Ulrich et al., 2016). The current study 281 
has demonstrated that (Pro3)GIP functions as an antagonist in horses at the concentration 282 
tested, but further studies would be required to determine if this effect is intensified, or 283 
indeed nullified, at lower or higher doses.  284 
 285 
Since the GIPR has been shown to undergo reduced recycling of the receptor to the cell 286 
membrane in response to ongoing ligand stimulation (Mohammad et al., 2014; Al-Sabah, 287 
2016), the effectiveness of GIPR antagonists may differ in vivo. Further, whether pancreatic 288 
eGIPR expression (density) differs between horses or ponies that are insulin-dysregulated and 289 
those that are not, as it does in humans, is important to investigate as this would further affect 290 
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pharmacodynamics in vivo (Ceperuelo-Mallafre et al., 2014). However, the insulin-291 
dysregulated ponies studied by de Laat et. al. (2016) did not show a significantly larger GIP 292 
response to an oral glucose load, when compared to normal control ponies, which suggests 293 
that its role in metabolic dysfunction requires further investigation. It is possible that GIP 294 
release may be more responsive to dietary fat in horses, and future studies on the role of 295 
lipids may be relevant (Schmidt et al., 2001). 296 
 297 
In rodents the GIPR is expressed on both the β and α-cells of the pancreatic islets, where GIP 298 
not only stimulates insulin secretion, but increases β-cell mass due to enhanced proliferation 299 
and decreased rates of apoptosis which reflect improved cell survival (Fujita et al., 2010). We 300 
examined whether β-cell fate was altered during incubation with GIP and (Pro3)GIP using 301 
markers for cell proliferation (PCNA) and apoptosis (caspase 3). Despite detecting no effect 302 
of GIP on these markers we suggest that the short incubation time may have prevented these 303 
effects from being sufficiently advanced to enable detection with the assays used. In 304 
comparison to GLP-1, the physiology of GIP in the pancreas is still poorly understood in all 305 
species, and further study will no doubt improve our capacity to fully determine the range of 306 
effects of this incretin hormone (Campbell and Drucker, 2013). 307 
 308 
Extra-pancreatic distribution of the eGIPR was also described in this study, which suggests 309 
that GIP may exert a multitude of effects in horses. Numerous extra-pancreatic effects, 310 
including effects beyond metabolic function, have been reported, and the GIPR is similarly 311 
expressed in a variety of tissues, in humans (Yamada et al., 2006; Renner et al., 2016). The 312 
presence of the eGIPR in the equine myocardium and small intestine is consistent with 313 
findings in rodents and humans (Usdin et al., 1993). The cardiovascular actions of GIP in 314 
other species include an increase in cardiovascular triglyceride metabolism, and the current 315 
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results suggest that GIP may affect cardiovascular function in horses which has identified an 316 
avenue for future investigation (Campbell and Drucker, 2013). The role of GIP in the equine 317 
liver and kidney also awaits investigation, considering that data regarding GIPR expression in 318 
these tissues is sparse (Usdin et al., 1993). Unfortunately, data on the extrapancreatic effects 319 
of GIP are scant in comparison with the detailed descriptions of the actions of another 320 
incretin, glucagon-like peptide-1 (GLP-1), in a range of tissues (Yamada et al., 2006; Ussher 321 
and Drucker, 2012; Campbell and Drucker, 2013).  322 
 323 
One extra-pancreatic effect of GIP that has received recent attention is its ability to promote 324 
obesity, and systemic GIP concentration is positively correlated with body mass index in 325 
humans (Calanna et al., 2013). Similarly, we have demonstrated that maximally-stimulated, 326 
circulating GIP concentrations were positively correlated with both BCS and CrNS in ponies, 327 
which suggests that GIP may promote obesity in ponies, as it has been shown to do in rodents 328 
(Zhou et al., 2005; Naitoh et al., 2008). However, whether the findings from the current study 329 
that used ponies can be applied to horses, which may differ in their predisposition to 330 
metabolic disease, requires investigation. The GIPR has been associated with the obesogenic 331 
actions of GIP as impaired receptor function has been correlated with insulin resistance in 332 
humans (Ceperuelo-Mallafre et al., 2014), and resistance to weight gain in GIPR knock-out 333 
rodent models following high-fat feeding (Miyawaki et al., 2002). If GIP modulates obesity 334 
in horses, then antagonism of endogenous GIP at the receptor may be expected to have 335 
positive effects on adiposity and metabolic dysfunction in this species.  336 
 337 
The CrNS is a commonly used marker of regionalised adiposity in horses, and nuchal crest 338 
adipose tissue has been shown to be metabolically active, not unlike visceral adipose deposits 339 
in humans (Burns et al., 2010; Pedersen et al., 2015).  The stronger correlation between 340 
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maximum post-prandial GIP concentrations and CrNS, compared to BCS, which is not 341 
necessarily a marker of metabolic dysfunction (Bamford et al., 2016; Ipsen et al., 2016), 342 
supports a role for GIP/R in equine metabolic dysfunction. A more in-depth investigation of 343 
the relationship between metabolic disease, regional adiposity and plasma GIP in horses, 344 
using a larger sample size, is warranted.  345 
 346 
This study has provided an important first step in proposing and investigating the feasibility 347 
of a novel therapeutic strategy for equine insulin dysregulation, and potentially even for the 348 
management of obesity. Given that horses with insulin dysregulation are often obese, it is 349 
possible that GIP antagonism may have two benefits. Firstly, attenuating post-prandial insulin 350 
secretion could reduce the considerable morbidity and mortality associated with insulin-351 
associated laminitis, a disease that currently lacks an effective treatment strategy. Secondly, 352 
GIP antagonists may be useful for addressing obesity in this species. 353 
 354 
Overall, this study has provided the first detailed examination of GIPR physiology in the 355 
horse, and has demonstrated a relationship between adiposity and circulating GIP in ponies. It 356 
has also detailed valuable, novel methodologies that can be used, and adapted, to further 357 
enhance islet biology research in horses. A commercially available agonist and antagonist of 358 
the GIPR were tested, with both compounds demonstrated to be functional at the eGIPR. 359 
These data may be useful in guiding future studies about the efficacy and appropriateness of 360 
manipulating the GIP axis for the treatment of metabolic disease in this species.   361 
 362 
363 
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TABLES 478 
Table 1. Isolated equine pancreatic islets incubated with the incretin GIP did not differ in 479 
mean ± s.e.m. caspase 3 or PCNA concentration compared to islets incubated with both GIP 480 
and the GIP antagonist (Pro3)GIP 481 
Marker Cellular process GIP GIP + (Pro3)GIP 
Caspase 3, pM Apoptosis 47.7 ± 1.47 45.4 ± 2.21
PCNA, ng/mL Proliferation 3.63 ± 0.68 3.69 ± 0.73
GIP: glucose-dependent insulinotropic polypeptide; PCNA: proliferating cell nuclear antigen  482 
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FIGURE LEGENDS 483 
Figure 1. The equine glucose-dependent insulinotropic polypeptide receptor (eGIPR) gene 484 
was expressed in the pancreas (positive control, +) as well as the heart (H), liver (L), kidney 485 
(K) and proximal small intestine (SI) of healthy horses (n = 4). There was also weak 486 
amplification of eGIPR in the digital lamellae of the left front foot (LF) and the tongue (T). 487 
However, there was no eGIPR gene expressed in the gluteal skeletal muscle (SM). The 488 
reference gene, GAPDH, was expressed in all tissues. The figure depicts representative 489 
results from one horse. 490 
 491 
Figure 2. A: The mean ± s.e.m. insulin production by isolated pancreatic islets was 492 
concentration-dependent with glucose up to 4 mM glucose and significantly greater than 493 
insulin production by pancreatic tissue explants at 4, 8 and 16 mM glucose. B: The mean ± 494 
s.e.m. insulin secretion by pancreatic islets was concentration-dependent with glucose-495 
dependent insulinotropic polypeptide (GIP) in horses (n = 5) up to 0.1µM (1x10-7 M). The 496 
basal insulin production (dotted line) was consistent with that expected in the presence of 497 
2.75 mM glucose in the incubation medium.  C: The insulin secretory response to GIP at 498 
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1x10-10 M was inhibited by 30% (P = 0.037) by the GIP receptor antagonist (Pro3)GIP at 499 
1x10-9 M. 500 
 501 
Figure 3. A: The maximum circulating glucose-dependent insulinotropic polypeptide (GIP) 502 
concentration (Cmax) reached in ponies (n = 9) following oral dextrose (0.75 g/kg) was 503 
positively correlated (Pearson’s co-efficient) with their body condition score. B: Similarly, 504 
the post-prandial GIP Cmax was positively correlated with cresty neck score in the same 505 
ponies. 506 
 507 
